Journal of Cardiovascular Pharmacology最新文献

Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure by activating the short-chain acyl-CoA dehydrogenase.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-08 DOI: 10.1097/FJC.0000000000001698

Chunyu Chen, Xue Qin, Yuhong Cao, Liyuan Qing, Zhichao Ma, Qingping Xu, Huan Peng, Guifang Jin, Zhicheng Yang, Jieyu Xing, Sigui Zhou

{"title":"Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure by activating the short-chain acyl-CoA dehydrogenase.","authors":"Chunyu Chen, Xue Qin, Yuhong Cao, Liyuan Qing, Zhichao Ma, Qingping Xu, Huan Peng, Guifang Jin, Zhicheng Yang, Jieyu Xing, Sigui Zhou","doi":"10.1097/FJC.0000000000001698","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001698","url":null,"abstract":"Flavin adenine dinucleotide (FAD), a cofactor that catalyzes the reaction of flavin protein, participates in fatty acid β-oxidation, which has been shown to inhibit pathological cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. However, the therapeutic advantage of FAD for heart failure treatment has not been investigated. This study aimed to explore the effects and underlying mechanisms of FAD in a transverse aortic constriction (TAC)-induced heart failure mouse model and in vitro tert-Butyl hydroperoxide (tBHP)-induced cardiomyocyte apoptosis model experiments. FAD considerably inhibited tBHP-induced cardiomyocyte apoptosis. In addition, FAD significantly increased the activity and expression of the short-chain acyl-CoA dehydrogenase (SCAD) enzyme and ATP content while reducing the content of free fatty acids and reactive oxygen species both in vitro and in vivo. Meanwhile, FAD increased the mitochondrial membrane potential, suppressed mitochondrial membrane swelling, and decreased myocardial fibrosis and TUNEL-positive apoptosis cells in the TAC-induced heart failure mice. In conclusion, our results indicate that FAD plays a positive role in preventing and treating heart failure, which can be attributed in part to the activation of SCAD.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XI as a Drug Target for the Prevention and Treatment of Thrombosis.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-08 DOI: 10.1097/FJC.0000000000001699

Nathaniel B Wayne, Sarah B Schaidle, Craig J Beavers

引用次数: 0

Roxadustat has beneficial effects on the vascular tone of the rat thoracic aorta.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-08 DOI: 10.1097/FJC.0000000000001697

Keisuke Nakagawa, Yoriko Oshiba, Reo Sukita, Ayaka Hosomi, Masashi Tawa, Mamoru Ohkita

{"title":"Roxadustat has beneficial effects on the vascular tone of the rat thoracic aorta.","authors":"Keisuke Nakagawa, Yoriko Oshiba, Reo Sukita, Ayaka Hosomi, Masashi Tawa, Mamoru Ohkita","doi":"10.1097/FJC.0000000000001697","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001697","url":null,"abstract":"Roxadustat, an agent for renal anemia, may have beneficial effects on the cardiovascular system, but its direct effects on the vasculature system have not been clarified. Therefore, in this study, the effect of roxadustat on vascular tone was examined using rat thoracic aortas and superior mesenteric arteries according to the organ chamber method. Roxadustat relaxed the thoracic aorta in the presence or absence of vascular endothelium, but the degree of vascular relaxation was attenuated by endothelium denudation, indicating that the majority of vasorelaxation caused by roxadustat is endothelium-dependent. Pretreatment with a nitric oxide (NO) synthase inhibitor (i.e., NG-nitro-L-arginine-methyl ester), a soluble guanylate cyclase (sGC) inhibitor (i.e., 1H-[1,2,4] oxadiazolo-[4,3-a]quinoxaline-1-one), and a bradykinin B2 receptor inhibitor (i.e., icatibant) significantly weakened roxadustat-induced vasorelaxation. In addition, roxadustat treatment of endothelium intact vascular rings increased mildly NO metabolites. When the direct effects of roxadustat on vascular smooth muscle were examined, various selective potassium channel inhibitors markedly diminished roxadustat-induced vasorelaxation in vascular endothelium-denuded rings. Moreover, roxadustat significantly inhibited angiotensin Ⅱ- and phenylephrine-induced vasocontraction, regardless of the presence of vascular endothelium. Not only the thoracic aorta, roxadustat relaxed the superior mesenteric artery, a smaller vessel. These results suggest that roxadustat-induced vasorelaxation of the thoracic aorta involves activation of endothelial NO synthase through bradykinin B2 receptors and the subsequent NO/sGC pathway. Furthermore, roxadustat probably inhibited vasocontraction by activating potassium channel opening.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoid Receptor Antagonist versus Placebo in a Patient With End-Stage Kidney Disease Under Renal Replacement Therapy: A Systematic Review and Meta-Analysis. 矿皮质激素受体拮抗剂与安慰剂在肾替代治疗的终末期肾病患者中的应用：系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001661

Sagun Dawadi, Dhan Bahadur Shrestha, Prakash Raj Oli, Jurgen Shtembari, Sajog Kansakar, Suman Paudel, Kailash Pant

{"title":"Mineralocorticoid Receptor Antagonist versus Placebo in a Patient With End-Stage Kidney Disease Under Renal Replacement Therapy: A Systematic Review and Meta-Analysis.","authors":"Sagun Dawadi, Dhan Bahadur Shrestha, Prakash Raj Oli, Jurgen Shtembari, Sajog Kansakar, Suman Paudel, Kailash Pant","doi":"10.1097/FJC.0000000000001661","DOIUrl":"10.1097/FJC.0000000000001661","url":null,"abstract":"Abstract: The number of patients living with chronic kidney diseases is increasing, and so are the patients with end-stage renal disease (ESRD) undergoing renal replacement therapy. Although there is a common understanding that these patients face higher risks of fatal or nonfatal cardiovascular and cerebrovascular events, and mineralocorticoid receptor antagonists (MRAs) have been an essential pillar in managing heart failure, their use in this subset of patients has been overshadowed because of concerns of hyperkalemia. Patients with ESRD under renal replacement therapy have often been excluded from landmark trials. This meta-analysis was conducted based on the PRISMA guideline after registering the protocol with PROSPERO (CRD42024499835). A database search included articles until April 2024, and relevant data were extracted from the included studies. Analysis was done using RevMan web (version 5.4). A total of 15 studies among 1086 studies were included in the final analysis. Our meta-analysis revealed MRA significantly reduced all-cause mortality (odds ratio (OR) 0.35, confidence interval (CI), 0.23-0.54) and cardiovascular mortality (OR 0.37, 0.21-0.65). With some possible increase in the risk of hyperkalemia (OR 1.56, CI, 1.01-2.42), with no discernible difference in the occurrence of stroke (OR 0.57, CI, 0.25-1.28) or myocardial infarction (OR 0.63, CI, 0.08-4.72). The utilization of MRA in patients with ESRD under dialysis is linked to improved mortality outcomes, albeit with slight concerns for hyperkalemia. Although current evidence leans toward MRA usage, prospective randomized controlled trials involving a broader patient cohort are essential to establish robust guidance for MRA application in this subset of patients.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"270-277"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronotropic Effects of Milrinone in a Guinea Pig Ex Vivo Model: A Pilot Study to Screen for New Mechanisms of Action.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001675

Piero Pollesello, Jouko Levijoki, Zoltán Papp

{"title":"Chronotropic Effects of Milrinone in a Guinea Pig Ex Vivo Model: A Pilot Study to Screen for New Mechanisms of Action.","authors":"Piero Pollesello, Jouko Levijoki, Zoltán Papp","doi":"10.1097/FJC.0000000000001675","DOIUrl":"10.1097/FJC.0000000000001675","url":null,"abstract":"Abstract: Positive inotropic responses upon administration of milrinone, an inhibitor of the phosphodiesterase enzyme (PDE), involve a well-pronounced positive chronotropic effect. Here, we tested whether milrinone evokes this chronotropic response solely by PDE inhibition or by a concerted action that involve additional pharmacological targets. Milrinone-stimulated increases in heart rate were studied in right atrial preparations of guinea pig in the presence or absence of inhibitors of putative ancillary molecular pathways or ion channels: ie, β receptor blockers with distinct selectivities (propranolol, metoprolol, and carvedilol), α1 receptor blocker (prazosin), inhibitor of the small conductance Ca 2+ activated K + (SK) channels (apamin), L-type Ca 2+ channel blockers (verapamil and diltiazem), and different Na + channel blockers (lidocaine, tetrodotoxin, and quinidine). Carvedilol, which inhibits β1, β2, α1, and 5-HT receptors, limited the positive chronotropic effects of milrinone to about 40%, ( P < 0.01). In the presence of another nonselective blocker of the β receptors, propranolol, and blockers of the l -type Ca 2+ channels, only nonsignificant trends toward reductions of the milrinone effects were seen. The α1 receptor blocker prazosin did not limit the milrinone-evoked positive chronotropy. Blockers of Na + channels, SK channels, or the β1 receptor blocker, metoprolol also did not affect the positive chronotropy evoked by milrinone. We conclude that milrinone increases heart rate in response to adrenergic signaling, which besides PDE inhibition, may involve a 5-HT receptor-dependent component. Our exploratory approach paves the way to more focused experiments with the use of selective 5-HT receptor antagonists to confirm or reject the involvement of a specific 5-HT receptor-dependent pathway.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"278-286"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-Induced Spontaneous Intramural Hematoma of the Gastrointestinal Tract: A Real-World Pharmacovigilance Analysis. 药物引起的自发性胃肠道血肿：现实世界的药物警戒分析。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001662

Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou

{"title":"Drug-Induced Spontaneous Intramural Hematoma of the Gastrointestinal Tract: A Real-World Pharmacovigilance Analysis.","authors":"Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou","doi":"10.1097/FJC.0000000000001662","DOIUrl":"10.1097/FJC.0000000000001662","url":null,"abstract":"Abstract: It is unclear whether drugs other than warfarin can cause spontaneous gastrointestinal intraluminal hematomas (SGIH). This study aimed to investigate the drugs that induced SGIH based on the US Food and Drug Administration's Adverse Event Reporting System data. A retrospective pharmacovigilance study was conducted. The disproportionality analysis was performed to assess the reports of drug-induced SGIH from the first quarter of 2004 to the fourth quarter of 2023. Logistics regression analysis was used to explore drug-related SGIH risk factors. Weibull distribution was applied for the onset time of SGIH. A total of 116 drugs associated with SGIH have been reported in the US Food and Drug Administration's Adverse Event Reporting System database. After removing duplicates, 88 unique drugs involving 210 patients were identified. These drugs can be broadly classified into 4 categories: (1) anticoagulants, (2) new direct oral anticoagulants, (3) antiplatelet agents, and (4) others. The first group is dominated by warfarin (59/210), while the second group, rivaroxaban, accounts for the most significant proportion (9/210). As for the third group, aspirin is the dominant drug (16/210), and for the fourth group, drugs that cause thrombocytopenia are dominant. The median number of reported cases was 11.5 per year, accounting for a median percentage of 0.0094% of all adverse events related to target drugs. The median time to drug-related SGIH onset was 12.5 days (interquartile range 1-220.25 days). When patients on the related drugs present with corresponding abdominal symptoms, it is crucial to consider the differential diagnosis of SGIH despite its low incidence.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"297-304"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colchicine in Coronary Artery Disease: Where Do We Stand?

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001672

Aldo Bonaventura, Nicola Potere, Luca Liberale, Simon Kraler, Brittany N Weber, Antonio Abbate

引用次数: 0

Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001673

Antonio Abbate, Giuseppe Biondi-Zoccai, Raffaele Altara, George W Booz

引用次数: 0

Patient-Reported Outcome Measures in Cardiovascular Research and Care: PRO(M)s and CONS.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001669

Giuseppe Biondi-Zoccai, Giacomo Frati, Mariangela Peruzzi, Marco Bernardi, Luigi Spadafora, Elena Tremoli

{"title":"Patient-Reported Outcome Measures in Cardiovascular Research and Care: PRO(M)s and CONS.","authors":"Giuseppe Biondi-Zoccai, Giacomo Frati, Mariangela Peruzzi, Marco Bernardi, Luigi Spadafora, Elena Tremoli","doi":"10.1097/FJC.0000000000001669","DOIUrl":"10.1097/FJC.0000000000001669","url":null,"abstract":"Abstract: Patient-reported outcome measures (PROMs) are vital tools in cardiovascular disease research and care, providing insights that complement traditional clinical outcomes such as mortality and morbidity. PROMs capture patient experiences with cardiovascular disease, such as quality of life, functional capacity, and emotional well-being, allowing clinicians to assess how interventions affect daily life. PROMs are integral to cardiovascular investigations and management, especially in chronic conditions and rehabilitation, where they inform on the impact of personalized care plans by tracking symptom progression and patient adherence. Selecting and applying to cardiovascular research and practice effective PROMs involves evaluating their validity, reliability, and sensitivity to change, with instruments such as the Kansas City Cardiomyopathy Questionnaire and the Seattle Angina Questionnaire widely used for heart failure and coronary artery disease, respectively. Implementing PROMs in real-world practice requires addressing challenges related to workflow integration and patient adherence, emphasizing their value in patient-centered care. As digital health advances, remote PROM data collection through mobile applications and wearable devices will enhance access to and extent of PROMs, and artificial intelligence-driven analytical tools will provide real-time, automated and plausible more poignant insights for personalized treatment. Future efforts should focus on culturally adapting PROMs for diverse populations to ensure global applicability. PROMs should also be established as essential components of innovative research and responsive, patient-centered cardiovascular care.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"261-266"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latest Evidence and Perspectives of Panax Notoginseng Extracts and Preparations for the Treatment of Cardiovascular Diseases.

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-04-01 DOI: 10.1097/FJC.0000000000001670

Chenyu Zhao, Jiamei Fu, Yingyu Wang, Yabin Zhou

{"title":"Latest Evidence and Perspectives of Panax Notoginseng Extracts and Preparations for the Treatment of Cardiovascular Diseases.","authors":"Chenyu Zhao, Jiamei Fu, Yingyu Wang, Yabin Zhou","doi":"10.1097/FJC.0000000000001670","DOIUrl":"10.1097/FJC.0000000000001670","url":null,"abstract":"Abstract: Cardiovascular diseases are a major cause of death worldwide, and their high incidence poses a significant threat to human health and public health systems. Panax notoginseng , a traditional Chinese medicinal herb with a long history, has shown promise in treating cardiovascular diseases. This review examines the diverse mechanisms through which Panax notoginseng addresses cardiovascular diseases, including anti-inflammatory, antiplatelet aggregation, anticoagulation, anti-oxidative stress, regulation of angiogenesis, antiatherosclerosis, improvement of microcirculatory disorders, and protection against myocardial ischemia-reperfusion injury, highlighting saponins as the principal active components. It also summarizes studies involving Panax notoginseng preparations like Xueshuantong and Xuesaitong in treating coronary heart disease and myocardial infarction, and discusses the safety, limitations, and future research directions of these extracts. In conclusion, the cardiovascular protective mechanism of Panax notoginseng is multitargeted and multipathways, and its clinical application is relatively safe, with rare and mild adverse drug reactions, suggesting a promising therapeutic potential.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"248-260"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0